Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient scheduling and engagement platform for multi-specialty practices, combining intelligent scheduling, reminders, and digital intake. Franklin TN, raised $41M+.
Relatient is a patient engagement and scheduling company that provides healthcare providers with an integrated platform for scheduling automation, appointment reminders, digital check-in, and patient communication. Founded in 2013 and headquartered in Franklin, Tennessee, Relatient has raised more than $41 million and serves health systems, hospital outpatient departments, and multi-specialty physician groups across the United States. The company's Dash platform delivers intelligent self-scheduling, automated reminder workflows, digital intake forms, and post-visit survey capabilities through a single system that integrates with major EHR and practice management software.\n\nRelatiently's Dash scheduling platform is built around intelligent appointment matching, directing patients to the right provider, location, and appointment type based on clinical criteria and insurance requirements rather than offering a simple open calendar view. This smart scheduling approach reduces scheduling errors and the downstream revenue cycle problems they cause, while improving the patient experience by eliminating the friction of calling and navigating phone trees. The platform supports scheduling across complex multi-provider, multi-location organizations where routing rules are an important operational requirement.\n\nRelatiently competes in a market that has grown significantly as providers recognize the revenue and operational impact of patient access optimization. The company differentiates through its depth of EHR integration, its focus on enterprise multi-specialty environments, and its comprehensive approach to the full patient engagement lifecycle from first contact through post-visit follow-up. Relatient's combination of scheduling intelligence and communication automation serves as an integrated patient access solution for organizations that need more than basic reminder tools.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.